论文部分内容阅读
目的观察亚砷酸(As2O3)联合小剂量阿糖胞苷(Ara-C)治疗慢性髓系白血病(CML)的临床疗效和不良反应。方法选择确诊为CML病例16例,其中慢性期(CML-CP)11例,加速期(CML-AP)5例;分别给予As2O3治疗28 d,同时给予小剂量Ara-C治疗14 d,总疗程28 d;每个病例均完成治疗。结果 16例中13例有效,3例未缓解。结论 As2O3联合小剂量Ara-C治疗CML的临床疗效好,不良反应较少。
Objective To observe the clinical efficacy and adverse reactions of arsenious acid (As2O3) combined with low dose of cytarabine (Ara-C) in the treatment of chronic myelogenous leukemia (CML). Methods Sixteen patients were diagnosed as CML, including 11 CML patients with chronic phase (CML-CP) and 5 patients with accelerated phase (CML-AP). The patients were treated with As2O3 for 28 days and given Ara-C for 14 days. 28 days; treatment completed in each case. Results of 16 cases, 13 cases were effective, 3 cases did not alleviate. Conclusion As2O3 combined with low-dose Ara-C treatment of CML has good clinical efficacy and few adverse reactions.